EGFR and metabolic dysfunction-associated steatotic liver disease: In this study, we found that using an FDA-approved de novo palmitate synthesis inhibitor, orlistat, to block NAFLD induced metabolism adaptation could inhibit EGFR palmitoylation and suppress CRLM in NAFLD, and orlistat treatment has a synergistic effect with conventional chemotherapy.